A citation-based method for searching scientific literature

Feng-Fei Li, Yun Shen, Rui Sun, Dan-Feng Zhang, Xing Jin, Xiao-Fang Zhai, Mao-Yuan Chen, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Diabetes Ther 2017
Times Cited: 7







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Bo Ahrén, Anja Schweizer, Sylvie Dejager, Beth E Dunning, Peter M Nilsson, Margaretha Persson, James E Foley. J Clin Endocrinol Metab 2009
136
42

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
42

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
Feng-Fei Li, Lan-Lan Jiang, Reng-Na Yan, Hong-Hong Zhu, Pei-Hua Zhou, Dan-Feng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Medicine (Baltimore) 2016
13
28

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Ippei Kanazawa, Ken-Ichiro Tanaka, Masakazu Notsu, Sayuri Tanaka, Nobuaki Kiyohara, Sayo Koike, Yuko Yamane, Yuko Tada, Motofumi Sasaki, Mika Yamauchi,[...]. Diabetes Res Clin Pract 2017
10
28


Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
24
28

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Valentina Lukashevich, Anja Schweizer, James E Foley, Sheila Dickinson, Per-Henrik Groop, Wolfgang Kothny. Vasc Health Risk Manag 2013
39
28

Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.
Feng-Fei Li, Lanlan Jiang, Liyuan Fu, Hong-Hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Diabetes Ther 2017
11
28


Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Soo Heon Kwak, You-Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang-Yong Kim, Jae Hyeon Kim. Diabetes Obes Metab 2020
6
33


Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii,[...]. Cardiovasc Diabetol 2020
21
28

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama,[...]. Diabetes Obes Metab 2020
6
33

Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Ryo Suzuki, Jun-Ichi Eiki, Takashi Moritoyo, Kenichi Furihata, Akira Wakana, Yukari Ohta, Shigeru Tokita, Takashi Kadowaki. Diabetes Obes Metab 2018
4
50

Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki, Mai Niitani, Kanako Kato, Takanori Tomotsune, Yoshimasa Aso. Diabetes Technol Ther 2014
17
28

The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee. Expert Opin Pharmacother 2017
15
28

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Bo Ahrén, James E Foley, Ele Ferrannini, David R Matthews, Bernard Zinman, Sylvie Dejager, Vivian A Fonseca. Diabetes Care 2010
66
28

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Yutaka Mori, Yukiko Taniguchi, Shigeru Miyazaki, Junichi Yokoyama, Kazunori Utsunomiya. Diabetes Technol Ther 2013
19
28

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes.
Fu-Ping Lyu, Bing-Kun Huang, Wei-Juan Su, Fang-Fang Yan, Jin-Yang Zeng, Zheng Chen, Yu-Xian Zhang, Shun-Hua Wang, Yin-Xiang Huang, Mu-Lin Zhang,[...]. Diabetes Ther 2020
2
100

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Anthony H Barnett, Bernard Charbonnel, Mark Donovan, Douglas Fleming, Roland Chen. Curr Med Res Opin 2012
135
14


Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetologia 2015
444
14


Potential cardiovascular effects of incretin-based therapies.
Carolyn F Deacon, Nikolaus Marx. Expert Rev Cardiovasc Ther 2012
17
14

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Sun A Yoon, Byoung G Han, Sung G Kim, Sang Y Han, Young I Jo, Kyung H Jeong, Kook H Oh, Hyeong C Park, Sun H Park, Shin W Kang,[...]. Diabetes Obes Metab 2017
9
14



Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
S Durán-Garcia, J Lee, H Yki-Järvinen, J Rosenstock, U Hehnke, S Thiemann, S Patel, H-J Woerle. Diabet Med 2016
7
14

Do we know the true mechanism of action of the DPP-4 inhibitors?
Emilie S Andersen, Carolyn F Deacon, Jens J Holst. Diabetes Obes Metab 2018
34
14


Incretin-based drugs and the risk of congestive heart failure.
Oriana Hoi Yun Yu, Kristian B Filion, Laurent Azoulay, Valerie Patenaude, Agnieszka Majdan, Samy Suissa. Diabetes Care 2015
40
14

Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
Theodora Nakouti, Apostolos K A Karagiannis, Konstantinos Tziomalos, Evangelos Cholongitas. Curr Vasc Pharmacol 2015
5
20

Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
56
14

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
Janet B McGill, Lance Sloan, Jennifer Newman, Sanjay Patel, Christophe Sauce, Maximilian von Eynatten, Hans-Juergen Woerle. Diabetes Care 2013
137
14

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2016
305
14

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
392
14

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Mark E Cooper, Vlado Perkovic, Janet B McGill, Per-Henrik Groop, Christoph Wanner, Julio Rosenstock, Uwe Hehnke, Hans-Juergen Woerle, Maximilian von Eynatten. Am J Kidney Dis 2015
61
14

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
14

Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.
Seiji Sato, Yoshifumi Saisho, Kinsei Kou, Shu Meguro, Masami Tanaka, Junichiro Irie, Toshihide Kawai, Hiroshi Itoh. PLoS One 2015
24
14

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus.
Hiroko Mori, Yosuke Okada, Tadashi Arao, Yoshiya Tanaka. J Diabetes Investig 2014
63
14


Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara,[...]. Diabetes Care 2016
91
14

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
161
14

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
14

Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure.
Chintan N Koyani, Ewald Kolesnik, Gerald Wölkart, Niroj Shrestha, Susanne Scheruebel, Christopher Trummer, Klaus Zorn-Pauly, Astrid Hammer, Petra Lang, Helga Reicher,[...]. Biochem Pharmacol 2017
20
14

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
G McInnes, M Evans, S Del Prato, M Stumvoll, A Schweizer, V Lukashevich, Q Shao, W Kothny. Diabetes Obes Metab 2015
59
14

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Janet B McGill, Hannele Yki-Järvinen, Susanne Crowe, Hans-Juergen Woerle, Maximilian von Eynatten. Diab Vasc Dis Res 2015
9
14

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg,[...]. Diabetes Care 2015
99
14

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Petra J W Pouwels, Indra C Pieters-van den Bos, Trynke Hoekstra, Michaela Diamant, Daniël H van Raalte, Djuna L Cahen. Diabetologia 2016
62
14

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Timo Rieg, Maria Gerasimova, Fiona Murray, Takahiro Masuda, Tong Tang, Michael Rose, Daniel J Drucker, Volker Vallon. Am J Physiol Renal Physiol 2012
102
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.